Welcome!

News Feed Item

Beauty School is In Session -- Create a No-Makeup, Makeup Look

Allergan, the makers of ACZONE®(dapsone) Gel 5% team up with celebrity makeup artist Julianne Kaye on new video tutorial

IRVINE, Calif., Aug. 20, 2014 /PRNewswire/ -- Renowned beauty expert and makeup artist to the stars Julianne Kaye is partnering with Allergan, the makers of ACZONE® (dapsone) Gel 5%, the No. 1 prescribed retinoid-free acne brand in the U.S., to offer expert skincare and makeup tips in an exclusive video posted today on www.aczone.com. 1 ACZONE® Gel is a prescription medicine used on your skin (topical) to treat acne in people 12 years and older.

"This time of year, my clients— particularly those with acne—are often concerned about being poolside or at the beach because it's not the best environment for heavy makeup," said Kaye. "The good news is you can still look fresh and pretty without loading on the concealer and foundation. That's why I am excited to partner with Allergan, the makers of ACZONE® Gel, to share tips and tricks for achieving one of my favorite looks. Makeup, of course, can only get you so far, so it's important to see a dermatologist to address any chronic skin conditions like acne."2

Acne is the most common skin condition in the United States, affecting 50 million Americans.3 Nearly 85% of people have acne at some point in their lives.3 In many cases, adults—particularly women—in their 20s, 30s, 40s, and even 50s can continue to have acne.3 However, people living with this chronic condition don't have to simply cope with their condition.2 Rather than self-treating or managing it alone, acne-sufferers can work with their dermatologist to identify treatments that are right for their skin and routine.

"The summer heat is not kind to acne-prone skin or the layers of makeup that we use to cover the blemishes and imperfections," said Doris Day, MD, MA, Clinical Associate Professor of Dermatology at New York University Langone Medical Center. "One medication I prescribe for acne lesions that can be worn under makeup is ACZONE® Gel. ACZONE® Gel does not make acne worse before it gets better. ACZONE® Gel is not known to cause sun sensitivity.4 And remember, sunscreen is a must-have regardless of your skin type."

To watch the video and for more skincare tips, please visit http://www.aczone.com/beauty-tips.

FDA-APPROVED USE
ACZONE® Gel is a prescription medicine used on your skin (topical) to treat acne in people 12 years and older.

IMPORTANT SAFETY INFORMATION
Do not use ACZONE® Gel if you are allergic to any of the ingredients in ACZONE® Gel or if you are younger than 12 years of age.

Tell your doctor about all of your medical conditions, including if you have glucose-6-phosphate dehydrogenase deficiency (G6PD) which may put you at a greater risk for developing a low red blood cell count. If you experience signs and symptoms such as back pain, breathlessness, tiredness/weakness with daily activities, dark-brown urine, high fever, and yellow or pale skin, stop use and call your doctor immediately.

The most common side effects of ACZONE® Gel are dryness, redness, oiliness, and peeling of the skin being treated.

Talk to your doctor about any medications you're using including topical benzoyl peroxide (BPO). Use of BPO with ACZONE® Gel may cause your skin to temporarily turn yellow or orange at the site of application.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information or visit www.aczone.com 

About Allergan

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 11,700 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.

Forward-Looking Statements

This press release contains "forward‐looking statements," including but not limited to, the statements by Ms. Kaye and Dr. Day as well as other statements regarding the safety and efficacy of ACZONE®. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; challenges related to achieving regulatory approval from the FDA on a timely and cost‐efficient manner; technological advances and patents attained by competitors; inconsistency of treatment results among patients; potential difficulties in manufacturing; challenges related to new product marketing, such as the unpredictability or market acceptance for new products and/or the acceptance of new indications for such products; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward‐looking statements except as required by law. Additional information concerning these and other risks can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's most recent Annual Report on Form 10‐K and any subsequent Quarterly Reports on Form 10‐Q. Copies of Allergan's press releases and additional information about Allergan are available at www.allergan.com or you can contact the Allergan Investor Relations Department by calling 1‐714‐246‐4636.

Allergan Contacts

Heather Katt (714)697-2981; (714)246-6224 (media)
Jessica Chao (714)586-7707; (714)246-3151 (media)

© 2014 Allergan, Inc.
® marks owned by Allergan, Inc.

APC62OJ14  

1 IMS Health, Inc. Monthly IMS National Prescription Audit Data. April 2008March 2014
2 Gollnick H et al. Can We Define Acne as a Chronic Disease? Am J Clin Dermatol. 2008:9(5): 279-284.
3 American Academy of Dermatology. "Stats and Facts: Acne." Available online at http://www.aad.org/mediaresources/stats-and-facts/conditions/acne. Last accessed on October 17, 2013.
4 DraelosZD, Carter E, Maloney JM, et al; For United States/Canada DapsoneGel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsonegel, 5% for the treatment of acne vulgaris. J Am AcadDermatol. 2007;56(3):439.e1-439.e10.

SOURCE Allergan

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
The deluge of IoT sensor data collected from connected devices and the powerful AI required to make that data actionable are giving rise to a hybrid ecosystem in which cloud, on-prem and edge processes become interweaved. Attendees will learn how emerging composable infrastructure solutions deliver the adaptive architecture needed to manage this new data reality. Machine learning algorithms can better anticipate data storms and automate resources to support surges, including fully scalable GPU-c...
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
Machine learning has taken residence at our cities' cores and now we can finally have "smart cities." Cities are a collection of buildings made to provide the structure and safety necessary for people to function, create and survive. Buildings are a pool of ever-changing performance data from large automated systems such as heating and cooling to the people that live and work within them. Through machine learning, buildings can optimize performance, reduce costs, and improve occupant comfort by ...
As Cybric's Chief Technology Officer, Mike D. Kail is responsible for the strategic vision and technical direction of the platform. Prior to founding Cybric, Mike was Yahoo's CIO and SVP of Infrastructure, where he led the IT and Data Center functions for the company. He has more than 24 years of IT Operations experience with a focus on highly-scalable architectures.
CI/CD is conceptually straightforward, yet often technically intricate to implement since it requires time and opportunities to develop intimate understanding on not only DevOps processes and operations, but likely product integrations with multiple platforms. This session intends to bridge the gap by offering an intense learning experience while witnessing the processes and operations to build from zero to a simple, yet functional CI/CD pipeline integrated with Jenkins, Github, Docker and Azure...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
Dhiraj Sehgal works in Delphix's product and solution organization. His focus has been DevOps, DataOps, private cloud and datacenters customers, technologies and products. He has wealth of experience in cloud focused and virtualized technologies ranging from compute, networking to storage. He has spoken at Cloud Expo for last 3 years now in New York and Santa Clara.
Enterprises are striving to become digital businesses for differentiated innovation and customer-centricity. Traditionally, they focused on digitizing processes and paper workflow. To be a disruptor and compete against new players, they need to gain insight into business data and innovate at scale. Cloud and cognitive technologies can help them leverage hidden data in SAP/ERP systems to fuel their businesses to accelerate digital transformation success.
Containers and Kubernetes allow for code portability across on-premise VMs, bare metal, or multiple cloud provider environments. Yet, despite this portability promise, developers may include configuration and application definitions that constrain or even eliminate application portability. In this session we'll describe best practices for "configuration as code" in a Kubernetes environment. We will demonstrate how a properly constructed containerized app can be deployed to both Amazon and Azure ...
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.